Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx Finalizes Phase 3 Study Design for DTX301 (OTC) with FDA
Apr 22, 2021
Posted by Ultragenyx